PFE · News · 20260923N

Oncology Portfolio Growth

PFIZER INC · 2026-09-23 · Importance 36 · Surprise 40

Pfizer’s newer and recently acquired medicines grew 18% year over year, with oncology products from the Seagen portfolio serving as a key growth driver. Padcev was identified as an important product helping offset shrinking COVID-19 sales and support longer-term revenue objectives. Investors are also watching upcoming clinical results for mevrometostat, a prostate cancer treatment, as a potential contributor to future portfolio growth.